# A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

> **NCT03197766** · PHASE3 · COMPLETED · sponsor: **BioMarin Pharmaceutical** · enrollment: 121 (actual)

## Conditions studied

- Achondroplasia

## Interventions

- **DRUG:** BMN 111
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03197766
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-12
- **Primary completion:** 2019-10-30
- **Final completion:** 2019-10-30
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03197766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03197766, "A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03197766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*